AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Enigma Biomedical Group Announces Appointment of Michael Reitermann to Their Board of Directors

November 18, 2019

TORONTO--(BUSINESS WIRE)--Nov 18, 2019--

Enigma Biomedical Group (EBG) today announced the appointment of Michael Reitermann to their Board of Directors effective December 1, 2019.

Michael Reitermann’s passion for innovation and its commercialization has driven his extensive career in the healthcare industry. After more than 20 years with Siemens Healthineers AG, he retired from the company in September 2019. Before, Michael held the position as Managing Board Member, head of in-vitro diagnostics business and head of global commercial operations and was part of the team leading the successful initial public offering (IPO) of Siemens Healthineers.

In prior roles, he was the Chief Operating Officer for Siemens Healthineers, CEO of Siemens Healthcare Diagnostics, Inc., President of the North American commercial organization and CEO of Siemens Healthcare’s Molecular Imaging business unit. Before joining Siemens Healthcare, he was part of Siemens Management Consulting, where he lead consulting projects in the areas of benchmarking, strategy, productivity and turnaround.

Mr. Reitermann received a Graduate Degree in Industrial Engineering from the University of Karlsruhe, Germany, and a Master of Business Administration from the University of British Columbia, Canada.

Lee-Anne Gibbs, President of Enigma Biomedical Group said, “The addition of Mr. Reitermann is an important evolution for our leadership team and critical to our growth and corporate positioning. We are delighted to have Michael provide his expertise and experience in supporting our mission.”

“I am looking forward to being part of the Enigma story and to help guide Enigma, and Enigma’s affiliate companies’ future strategies.” said Mr. Reitermann. “The Enigma group of companies’ unique strategy and positioning is proving to be a critical contributor in the development of therapeutic solutions used to combat neurodegenerative disease and I am personally excited to contribute to the acceleration of Enigma’s development.”

“Enigma, and our affiliate companies, are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health,” said Rick Hiatt, Chief Executive Officer of Enigma Biomedical Group and President and CEO of Cerveau Technologies, Inc. “We are thrilled to have Michael join our team and help us develop our long-term strategies and support our future direction.”

About Enigma Biomedical Group
Toronto-based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research.

About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a collaboration between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005484/en/

CONTACT: Enigma Biomedical Group

Lee-Anne Gibbs

Lee@enigmabiomedicalgroup.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Enigma Biomedical Group

Copyright Business Wire 2019.

PUB: 11/18/2019 09:07 AM/DISC: 11/18/2019 09:07 AM

http://www.businesswire.com/news/home/20191118005484/en